Q: What is Jivi and how does it work?

The active substance in Jivi , damoctocog alfa pegol, works in the same way as the body’s factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of the bleeding disorder.

Q: How old do you have to be to get Jivi?

Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A. Your healthcare provider may also give you Jivi when you have surgery.

Q: How do I contact the FDA about Jivi antihemophilic factor?

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Jivi antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:

Q: How do I tell my doctor that I take Jivi?

Tell all of your health care providers that you take Jivi (antihemophilic factor (recombinant [pegylated-aucl])). This includes your doctors, nurses, pharmacists, and dentists. Have blood work checked as you have been told by the doctor. Talk with the doctor.

Q: What is Jivi used to treat?

Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A. Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A.

Q: Is Jivi approved in the EU?

The European Medicines Agency decided that Jivi ’s benefits are greater than its risks and it can be authorised for use in the EU. Studies show that Jivi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.

Q: What is Jivi antihemophilic factor?

Jivi antihemophilic factor (previously BAY 94-9027) is an approved prophylactic or preventive treatment for hemophilia type A patients, ages 12 or older. Developed by Bayer, it is given as an infusion into the bloodstream and also can be used on-demand in response to a bleed.

Question 1

What is Jivi and how does it work?

Accepted Answer

The active substance in Jivi, damoctocog alfa pegol, works in the same way as the body’s factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of the bleeding disorder.

Question 2

How old do you have to be to get Jivi?

Accepted Answer

Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A. Your healthcare provider may also give you Jivi when you have surgery.

Question 3

How do I contact the FDA about Jivi antihemophilic factor?

Accepted Answer

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Jivi antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:

Question 4

How do I tell my doctor that I take Jivi?

Accepted Answer

Tell all of your health care providers that you take Jivi (antihemophilic factor (recombinant [pegylated-aucl])). This includes your doctors, nurses, pharmacists, and dentists. Have blood work checked as you have been told by the doctor. Talk with the doctor.

Question 5

What is Jivi used to treat?

Accepted Answer

Jivi is an injectable medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A. Jivi is used to treat and control bleeding in previously treated adults and adolescents (12 years of age and older) with hemophilia A.

Question 6

Is Jivi approved in the EU?

Accepted Answer

The European Medicines Agency decided that Jivi’s benefits are greater than its risks and it can be authorised for use in the EU. Studies show that Jivi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.

Question 7

What company makes Jivi?

Accepted Answer

Developed by Bayer, it is given as an infusion into the bloodstream and also can be used on-demand in response to a bleed. How does Jivi work? Hemophilia type A is an inherited condition that results due to a mutation in the coagulation factor 8, or F8 gene.

Question 8

What is Jivi antihemophilic factor?

Accepted Answer

Jivi antihemophilic factor (previously BAY 94-9027) is an approved prophylactic or preventive treatment for hemophilia type A patients, ages 12 or older. Developed by Bayer, it is given as an infusion into the bloodstream and also can be used on-demand in response to a bleed.

Jivi Quick Start

Listing Results Jivi Quick Start

JIVI FDA

Jivi - FDA prescribing information, side effects and uses

Home

Jivi® Official Healthcare Professionals Site

Jivi , PEGylated-aucl

Jivi European Medicines Agency

Џиви - Jivi

Jivi: Truly Natural Skin Care that's Safe Enough to Eat

Jivi App Store - Review & Free Download

Monitoring Jivi® antihemophilic factor (recombinant

ELTIZAM - JIVI Solutions

Jivi: Indications, Side Effects, Warnings - Drugs.com

About Jivi Solutions – ELTIZAM – Workforce Management

Frequently Asked Questions